Week in Review: FDA warning on contrast | Breast density reporting | AMVC 2022 wrap-up

Dear AuntMinnie Member,

Clinicians should be sure to follow up on pediatric patients younger than 3 years old who receive iodinated contrast due to the risk of problems with thyroid function, according to an advisory issued March 30 by the U.S. Food and Drug Administration (FDA).

The FDA said that iodinated contrast could have an impact on thyroid function of children who already have an underactive thyroid or a temporary decrease in thyroid hormone levels. These individuals should be monitored for three weeks after contrast administration, according to the advisory. Learn more in an article in our CT Community.

In other CT news:

Breast density reporting

The density of breast tissue has become known as a major predictor for the risk of breast cancer in women. But how radiologists convey density information to women could use improvement.

That's according to a recent study by researchers from New Hampshire that was published in the Journal of the American College of Radiology. They noted that how women receive density notifications can vary widely by state -- indicating that a federal standard could be needed.

Also in the Imaging Leaders Community:

You'll find more stories like these about the business of healthcare in our Imaging Leaders Community.

AMVC 2022 wrap-up

Finally, thanks to everyone who attended our Spring 2022 Virtual Conference: AI, Women's Imaging, and More, this week. It was a great event, with two days of engaging presentations by key opinion leaders in radiology.

If you weren't able to make the event, or would like to view a presentation again, we'll be posting them on AuntMinnie.com next week.

Page 1 of 100
Next Page